Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merrimack Pharmaceuticals has completed the enrollment in a Phase II trial of 100 patients that evaluates the safety and efficacy of its lead product, MM-093, in patients suffering from rheumatoid arthritis.
Subscribe to our email newsletter
The randomized, double-blind, placebo-controlled, Phase II study is being conducted at 20 centers throughout the US. The objective of this study is to examine the safety and efficacy of MM-093 in patients with moderate to severe, active rheumatoid arthritis despite treatment with stable doses of methotrexate.
William Slichenmyer, senior vice president and chief medical officer at Merrimack, said: “We believe MM-093 represents a promising and novel approach to the treatment of a broad range of autoimmune diseases. We look forward to completing the study and communicating the results later this year.”